IL-7及IL-15在肿瘤免疫疗法中的应用

被引：1
|
作者：
聂文冰
尹鸿萍
机构：
[1] 中国药科大学
来源：
药学研究 | 2020年 / 39卷 / 01期
关键词：
嵌合抗原受体T细胞; 白细胞介素-7; 白细胞介素-15; 肿瘤免疫;
D O I：
10.13506/j.cnki.jpr.2020.01.011
中图分类号：
R730.51 [免疫疗法];
学科分类号：
摘要：
嵌合抗原受体T细胞(CAR-T)免疫疗法经过体外将正常T细胞进行基因修饰后,再回输入患者体内,以非人类白细胞抗原(HLA)依赖性方式识别肿瘤细胞并进行杀伤。自2017年美国食品药品监督管理局(FDA)批准了诺华及Kite公司两款嵌合抗原受体T细胞产品上市以来,嵌合抗原受体T细胞疗法在全球展开蓬勃发展。白细胞介素-2(IL-2)、白细胞介素-4(IL-4)、白细胞介素-7(IL-7)、白细胞介素-15(IL-15)、白细胞介素-21(IL-21)等细胞因子可促使嵌合抗原受体T细胞在体外有效增殖。本文主要对白细胞介素-7及白细胞介素-15进行阐述,探讨其作用机理以及临床应用。
引用
收藏
页码：49 / 52
页数：4
相关论文
共 8 条
  • [1] Effect of interleukin-7 gene transfection into ovarian carcinoma cell line SKOV3 in vitro and in vivo[J] . Xing Xie,Da-Feng Ye,Huai-Zeng Chen,Wei-Guo Lu,Yun-Feng Fu,Bei Cheng,Hua Zhu. &nbspGynecologic Oncology . 2003 (2)
  • [2] Effect of interleukin-7 gene transfection into ovarian carcinoma cell line SKOV3 in vitro and in vivo[J] . Xing Xie,Da-Feng Ye,Huai-Zeng Chen,Wei-Guo Lu,Yun-Feng Fu,Bei Cheng,Hua Zhu. &nbspGynecologic Oncology . 2003 (2)
  • [3] Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody–Activated Chimeric Antigen Receptor–Modified T Cells[J] . Michael Schmueck-Henneresse,Bilal Omer,Thomas Shum,Haruko Tashiro,Maksim Mamonkin,Natalia Lapteva,Sandhya Sharma,Lisa Rollins,Gianpietro Dotti,Petra Reinke,Hans-Dieter Volk,Cliona M. Rooney. &nbspThe Journal of Immunology . 2017 (1)
  • [4] Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody–Activated Chimeric Antigen Receptor–Modified T Cells[J] . Michael Schmueck-Henneresse,Bilal Omer,Thomas Shum,Haruko Tashiro,Maksim Mamonkin,Natalia Lapteva,Sandhya Sharma,Lisa Rollins,Gianpietro Dotti,Petra Reinke,Hans-Dieter Volk,Cliona M. Rooney. &nbspThe Journal of Immunology . 2017 (1)
  • [5] In Vivo Expansion and Antitumor Activity of Coinfused CD28-and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia
    Cheng, Zhi
    Wei, Runhong
    Ma, Qiuling
    Shi, Lin
    He, Feng
    Shi, Zixiao
    Jin, Tao
    Xie, Ronglin
    Wei, Baofeng
    Chen, Jing
    Fang, Hongliang
    Han, Xiaolu
    Rohrs, Jennifer A.
    Bryson, Paul
    Liu, Yarong
    Li, Qi-Jing
    Zhu, Bo
    Wang, Pin
    [J]. MOLECULAR THERAPY, 2018, 26 (04) : 976 - 985
  • [6] In Vivo Expansion and Antitumor Activity of Coinfused CD28-and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia
    Cheng, Zhi
    Wei, Runhong
    Ma, Qiuling
    Shi, Lin
    He, Feng
    Shi, Zixiao
    Jin, Tao
    Xie, Ronglin
    Wei, Baofeng
    Chen, Jing
    Fang, Hongliang
    Han, Xiaolu
    Rohrs, Jennifer A.
    Bryson, Paul
    Liu, Yarong
    Li, Qi-Jing
    Zhu, Bo
    Wang, Pin
    [J]. MOLECULAR THERAPY, 2018, 26 (04) : 976 - 985
  • [7] The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity
    Thistlethwaite, Fiona C.
    Gilham, David E.
    Guest, Ryan D.
    Rothwell, Dominic G.
    Pillai, Manon
    Burt, Deborah J.
    Byatte, Andrea J.
    Kirillova, Natalia
    Valle, Juan W.
    Sharma, Surinder K.
    Chester, Kerry A.
    Westwood, Nigel B.
    Halford, Sarah E. R.
    Nabarro, Stephen
    Wan, Susan
    Austin, Eric
    Hawkins, Robert E.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (11) : 1425 - 1436
  • [8] The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity
    Thistlethwaite, Fiona C.
    Gilham, David E.
    Guest, Ryan D.
    Rothwell, Dominic G.
    Pillai, Manon
    Burt, Deborah J.
    Byatte, Andrea J.
    Kirillova, Natalia
    Valle, Juan W.
    Sharma, Surinder K.
    Chester, Kerry A.
    Westwood, Nigel B.
    Halford, Sarah E. R.
    Nabarro, Stephen
    Wan, Susan
    Austin, Eric
    Hawkins, Robert E.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (11) : 1425 - 1436
1